DRMAW DERMATA THERAPEUTICS INC C/WTS (TO PUR COM)
- 0.0170
- +0.0001+0.59%
DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) News
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
Dermata to Present at the Emerging Growth Conference on April 3, 2024
- Dermata to provide a corporate update followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
Dermata to Present at the Emerging Growth Conference on February 7, 2024
- Company to provide a corporate overview followed by a live question and answer session -SAN DIEGO, CA / ACCESSWIRE / February 1, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Derma
Why Dermata Therapeutics Stock Took Off After-Hours
Dermata Therapeutics, Inc. (NASDAQ:DRMAW) shares are trading higher in Thursday's after-hours session after the company announced the issuance of a new patent in Japan for its DMT410 program for the
Dermata Expands Global Intellectual Patent Portfolio With Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment o
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 -- Completed
Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial
- Dermata is prepared to initiate DMT310 Phase 3 STAR-1 clinical trial by the end of 2023 -- Investigational sites have been selected -- Clinical trial materials are ready to be shipped to investigati
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback on its End of Phase 2 meeting package from FDA in June 2023 -- Phase 3 ST
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA, DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical a
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, a
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / May 26, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical a
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq RulesSAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Dermata raised $5 million gross proceeds from a public offering in March 2023 -- Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 -- FDA agreed that Dermata's chemistry, manu
Dermata Announces Receipt of Type C Meeting Response From the FDA and Submission of DMT310 End of Phase 2 Meeting Package
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies-- Dermata also submitted an end of phase 2 meeting package to the FDA -SAN DIEGO, CA / ACCESSWIRE / Ap
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial program in moderate-to-severe acne patients expected in 2H 2
Analysis
Price Target
No Data
